NASDAQ:PPBT Purple Biotech Q2 2026 Earnings Results & Report $1.33 -0.11 (-7.64%) Closing price 10/9/2026 04:00 PM EasternExtended Trading$1.32 -0.01 (-0.75%) As of 10/9/2026 07:38 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Purple Biotech beat analyst earnings expectations in its Q2 2026 results, released August 7, 2026. The company reported EPS of $1.07 versus the -$0.98 consensus estimate. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ2 2026Report DateAugust 7, 2026TimeBefore Market Opens Purple Biotech EPS ResultsActual EPS$1.07Consensus EPS -$0.98Beat/MissBeat by +$2.05One Year Ago EPSN/AEPS Beat Rate3 of last 8 quartersPurple Biotech Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AUpcoming EarningsPurple Biotech's next earnings date is estimated for Friday, November 13, 2026, based on past reporting schedules. Conference Call ResourcesEarnings HistoryCompany Profile Purple Biotech Q2 2026 Earnings FAQ Did Purple Biotech beat earnings estimates for Q2 2026? Purple Biotech (NASDAQ:PPBT) reported earnings of $1.07 per share for Q2 2026, beating the consensus estimate of -$0.98. The report was announced on Friday, August 7, 2026. When is Purple Biotech's next earnings date? Purple Biotech's next earnings date is estimated for Friday, November 13, 2026. MarketBeat tracks confirmed and estimated earnings dates for Purple Biotech on the company's earnings history page. Purple Biotech Earnings HeadlinesPurple Biotech US patent allowance strengthens CAPTN-3 multispecific antibody protectionSeptember 2, 2026 | msn.comNew U.S. Patent Allowance Strengthens Protection for CAPTN-3 Modular Platform for Next-Generation Multispecific AntibodiesSeptember 2, 2026 | globenewswire.comNo. 1 stock to cash in on the death of iPhoneAnalyst Josh Baylin, who warned Congress about smartphones years before the iPhone launched, says the world's richest man may be building an iPhone rival he calls Starphone. Baylin points to FCC rulings, two trademarks filed the same day, multibillion-dollar spectrum deals, chip partnerships, and a string of posts from Elon Musk as evidence pointing to one conclusion. See the full research and the stock Baylin is watching now.October 10 at 1:00 AM | Stansberry Research (Ad)Purple Biotech Unveils August 2026 Corporate Update on Tri-Specific Immuno-Oncology PlatformAugust 12, 2026 | theglobeandmail.comPurple Biotech Reports Second Quarter 2026 Financial ResultsAugust 7, 2026 | markets.businessinsider.comPurple Biotech presents new IM1240 preclinical data showing anti-tumor activity and broad therapeutic window (PPBT)June 12, 2026 | msn.comSee More Purple Biotech Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Purple Biotech? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Purple Biotech and other key companies, straight to your email. Email Address About Purple BiotechPurple Biotech (NASDAQ:PPBT) Ltd. is an Israel-based clinical-stage biopharmaceutical company focused on developing therapies for cancer. The company’s research programs are designed to address mechanisms that contribute to tumor growth, immune evasion and resistance to existing treatments. Purple Biotech’s principal product candidates have included CM24, an investigational monoclonal antibody targeting CEACAM1, an immune checkpoint that may help tumors avoid immune-system detection, and NT219, an investigational small-molecule oncology therapy designed to inhibit signaling pathways associated with resistance to cancer treatments. The company has evaluated these candidates in combination with other anticancer therapies, including immune checkpoint inhibitors. The company was formerly known as Kitov Pharma Ltd. and adopted the Purple Biotech name as part of a broader focus on oncology. Purple Biotech is headquartered in Rehovot, Israel, and its development activities have involved clinical research conducted in collaboration with medical institutions and partners in multiple countries. Its therapies remain investigational and have not been established as approved commercial products.View Purple Biotech ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles MarketBeat Week in Review – 10/05 - 10/09Delta Air Lines Faces a Fuel Crisis—But There's a Silver LiningPalantir’s Rally Puts Wall Street in Catch-Up Mode Ahead of November EarningsApplied Digital’s Hidden Moat Could Unlock Massive UpsideLevi's Stock Dip Reveals Value Opportunity Despite Q3 HeadwindsTilray Finds a Path to Growth Without Waiting on U.S. Cannabis ReformPepsiCo Stock Looks Poised to Bottom With High Yield, Deep Value Upcoming Earnings Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026)Wells Fargo & Company (10/13/2026)Johnson & Johnson (10/13/2026)UnitedHealth Group (10/13/2026)Bank of America (10/14/2026)BlackRock (10/14/2026)Morgan Stanley (10/14/2026)Progressive (10/14/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
